文献速递血栓与止血

FVIIIa模拟双特异性抗体与FVIII的内在差异阻碍FVIII等效性赋值

Intrinsic differences between FVIIIa mimetic bispecific antibodies and FVIII prevent assignment of FVIII-equivalence.
PubMed 文献 · J Thromb Haemost · 2019-04-26

本研究比较序列相同的艾美赛珠单抗(SI-Emi)、BS-027125与重组FVIII在临床及非临床检测中的活性,发现双特异性抗体在不同检测中FVIII样活性差异大,且与FVIII存在内在差异,难以赋予FVIII等效值。

要点

  • SI-Emi和BS-027125的FVIII样活性在不同检测及参数间差异大。
  • SI-Emi抗FIXa同源二聚体在多个检测中有活性,而BS-027125仅在显色检测中有活性。
  • 双特异性抗体与FVIII的内在差异使FVIII等效值赋值复杂化。

核心结论

  • 双特异性抗体与FVIII的内在差异导致所测检测间一致性差,复杂化FVIII等效值赋值。
  • 需深入理解双特异性抗体机制并开发定制检测以监测和预测其止血潜力及长期疗效安全性。

研究设计与样本

  • 采用一期凝血检测、显色因子Xa生成检测和凝血酶生成检测比较SI-Emi、BS-027125与重组FVIII的活性。
  • 评估各双特异性抗体抗FIXa和抗FX双价同源二聚体的活性,并探究凝血酶生成检测中不同试剂的影响。

主要发现

  • SI-Emi和BS-027125的FVIII样活性在不同检测间差异大,且随检测内参数和所用试剂变化。
  • SI-Emi抗FIXa双价同源二聚体在多个检测中有显著活性,而BS-027125抗FIXa双价同源二聚体仅在显色检测中有活性。
  • SI-Emi在无磷脂条件下显示活性,而BS-027125的磷脂非依赖性活性极低。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

UNLABELLED: Essentials Non-factor VIII (FVIII) therapies for hemophilia A, such as bispecific antibodies (bsAbs), are in development. Bispecific antibodies are intrinsically different from FVIII and lack many of the same regulatory mechanisms. These differences complicate assignment and interpretation of FVIII-equivalent activity. Inability to assign FVIII equivalence compromises our capacity to assess hemostatic potential of bsAb therapies. BACKGROUND: Activated factor VIII (FVIIIa) mimetic bsAbs aim to enable prophylactic treatment of hemophilia A patients with and without inhibitors. With different mechanisms of action, benchmarking their activity against FVIII to determine efficacious yet safe dosage is difficult. OBJECTIVE: To compare the activities of sequence identical emicizumab (SI-Emi) and another bsAb, BS-027125, to recombinant FVIII (rFVIII) using clinical and nonclinical assays and to evaluate our ability to assign a FVIII-equivalent value to bsAbs and implications thereof. METHODS: Activities of SI-Emi, BS-027125, and rFVIII were measured by one-stage clotting assay, chromogenic factor Xa generation assay, and thrombin generation assay. We also assessed the activity of anti-FIXa and anti-FX bivalent homodimers of each bsAb and probed the effect of different reagents in thrombin generation assay (TGA). RESULTS: The FVIII-like activity of SI-Emi and BS-027125 ranged greatly across each assay, varying both by parameter measured within an assay and by reagents used. Notably, SI-Emi anti-FIXa bivalent homodimer had meaningful activity in several assays, whereas BS-027125 anti-FIXa bivalent homodimer only had activity in the chromogenic assay. Surprisingly, SI-Emi displayed activity in the absence of phospholipids, while BS-027125 had minimal phospholipid-independent activity. CONCLUSIONS: Bispecific antibodies demonstrate little consistency between assays tested here owing to intrinsic differences between FVIII and bsAbs. While some trends are shared, the bsAbs also differ in mechanism. These inconsistencies complicate assignment of FVIII-equivalent values to bsAbs. Ultimately, a deeper mechanistic understanding of bsAbs as well as bsAb-tailored assays are needed to monitor and predict their hemostatic potential and long-term efficacy and safety confidently.

来源:J Thromb Haemost,查看原文。版权归原作者所有。

引用

  1. Leksa NC, Aleman MM, Goodman AG, et al. Intrinsic differences between FVIIIa mimetic bispecific antibodies and FVIII prevent assignment of FVIII-equivalence. J Thromb Haemost. 2019. PMID: 30887655. doi:10.1111/jth.14430

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。